To investigate the clinical relevance of SERT, we conducted a correlation analysis of SERT gene expression in whole-tumor lysate transcriptome data with clinical patient outcomes by using the tumor immune dysfunction and exclusion (TIDE) computational method.84 We observed that intratumoral SERT expression levels were negatively correlated with patient survival in a broad range of solid cancers, spanning melanoma, breast cancer, lung cancer, kidney cancer, and sarcoma (Figure 6Q). Here, SLC6A4 is linked to neoplasm.